March 11, 2022
(press release)
–
Co-founded by Trinity Health, Civica to tackle high cost of insulin, continuing to ensure patients and their needs come first. Civica Rx today announced plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at significantly lower prices than insulins currently on the market. The availability of affordable insulins will benefit people with diabetes who have been forced to choose between life sustaining medicines and living expenses, particularly those uninsured or underinsured who often pay the most out of pocket for their medications. Trinity Health, along with hospital systems Intermountain Healthcare, Ascension, and SSM Health formed Civica Rx in 2018 to supply certain generic drugs in order to challenge the pricing practices of drug makers that have hiked the prices of older, off-patent medicines, as well as to stave off drug shortages, which have become increasingly common in recent years. "Today's announcement shows us what is possible when we work together,” said Lou Fierens, Executive Vice President, Administrative Services at Trinity Health, Civica Rx Board member and Civica Foundation Board Chair. “Providing insulin at an affordable price will undoubtedly improve the health and lives of countless people, particularly those who are most vulnerable in our communities. Trinity Health believes that every person deserves access to affordable healthcare and medications, and we are proud to partner with Civica Rx to lead this effort.” Read the media release here. More information on this initiative, including commentary from partners and a fact sheet, can be found at civicainsulin.org.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
